Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma
International Journal of Immunopathology and Pharmacology · 2025
DOI: 10.1177/03946320251316692 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2025. Verfasst von Mubalake Abudoureyimu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Affiliated Jinling Hospital, Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Quinolines, Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This study aimed to investigate whether the dysregulation of Aurora-A is involved in lenvatinib resistance in hepatocellular carcinoma.
Methods
Bioinformatics tools and drug sensitivity assays were used to investigate the association between Aurora-A expression level and lenvatinib resistance in hepatocellular carcinoma cell lines. Cell function experiments had performed after treatment with lenvatinib and/or a selective Aurora-A inhibitor (MLN-8237). CircRNA microarray, RIP, RNA pull-down, and dual-luciferace reporter assay were performed to identify the downstream molecular mechanism of Aurora-A dysregulation.
Results
Aurora-A expression was positively correlated with lenvatinib resistance in hepatocellular carcinoma cells. The Aurora-A selective inhibitor MLN-8237, in combination with lenvatinib, synergistically inhibited hepatocellular carcinoma cell proliferation in vitro and vivo, suggesting the Aurora-A might be a potential therapeutic target for lenvatinib resistance. Mechanistically, Aurora-A induced FGFR1 expression through the hsa-circ-0058046/miR-424-5p/FGFR1 axis. Aurora-A promotes lenvatinib resistance through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma cells. The simultaneous inhibition of FGFR1 by the Aurora-A inhibitor MLN-8237 and lenvatinib overcame lenvatinib resistance in hepatocellular carcinoma cells.
Conclusion
Collectively, our findings indicate that Aurora-A promotes lenvatinib resistance through the hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma (HCC) cells. These results suggest that Aurora-A may serve as a therapeutic target for HCC patients exhibiting lenvatinib resistance. Furthermore, the combination of lenvatinib and MLN-8237 shows potential for clinical trials aimed at overcoming lenvatinib resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Affiliated Jinling Hospital, Medical School, Nanjing University, Nanjing, China.
- Department of Medical Oncology, Affiliated Jinling Hospital, Nanjing Medical University, Nanjing, China.
ORCID-Profile: Rui Wang
Zitieren
APA
Abudoureyimu, M., Sun, N., Chen, W., Lin, X., Pan, F., & Wang, R. (2025). Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320251316692
Vancouver
Abudoureyimu M, Sun N, Chen W, Lin X, Pan F, Wang R. Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma. International Journal of Immunopathology and Pharmacology. 2025. doi:10.1177/03946320251316692
BibTeX
@article{Abudoureyimu2025,
author = {Abudoureyimu, Mubalake and Sun, Ni and Chen, Weiwei and Lin, Xinrong and Pan, Fan and Wang, Rui},
title = {Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2025},
doi = {10.1177/03946320251316692}
}
EUVIMED